

An all-RNA platform for safe-harbor gene insertion

Christian Dombrowski Company name: Avera Therapeutics Website:
<https://avernatx.com> CEO name: Thomas M. Barnes

CATEGORY: Biotech/Pharma SESSION: "Rewriting Biology In Vivo: The Age of Cellular Reprogramming."

- Executive Summary / Investment Rational: We are a complete RNA-LNP company, with a unique combination of a proprietary all-RNA safe harbor integrating payload based on the retrotransposon R2, and a proprietary radically-simplified targeted LNP platform called HALO. We are developing programs for oncology and autoimmune disease using T cell-targeted delivery, and for metabolic and rare disease using liver-targeted delivery.
- Core Technology: Among genome-manipulating technologies, a major white space is the ability to stably and safely insert gene-length information into cells of choice using an all-RNA payload and LNP delivery. We have built such a platform. This allows us to provide genes that a patient lacks (eg in genetic disease), as well as genes that a patient should have (eg in-vivo CAR).
- Product Profile/Pipeline: Using immunotropic LNPs, we are building products for oncology and beyond that will reprogram immune cells within the patient to fight disease. Using hepatotropic LNPs, we are building products to correct genetic disease, as well as to reprogram metabolism. We are currently preclinical.
- Business Strategy: We are a product-focused biotechnology company that will create value by advancing our own pipeline, as well as by partnering strategically across products and technology.
- What's Next? In 2026 we will publicize our initial pipeline of programs